Tasly Biopharmaceuticals Co., Ltd.

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
T101No recent activity
Phase 2
HBV core, polymerase and envelope antigensBiologic (subtype unspecified)
Chronic Hepatitis B

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.